In vitro diagnosis: at home and abroad | '4 big family'

Medical News IVD January 2 industry is very popular, what is the difference between China and foreign countries?

Due to historical reasons, China's in vitro diagnostic techniques are introduced from overseas, the study of overseas giants on China's industry development direction and company development has a good guiding role in 2016 global in vitro diagnostic industry market concentration is high, the first four in vitro diagnostic Over the past decade, through mergers and acquisitions continue to expand the industry, the current four companies occupy a total of 48.5% of the in vitro diagnostic market market share, can be described as 'four major' control half of the country.

(1) Roche: leader in global diagnostics, who dominate the industry and compete

Roche is the largest biotech company in the world, according to consulting statistics, Roche earned $ 10.157 billion in diagnostic business sales in 2016, ranking the first in global diagnostics, reaching 18.3%.

The company started its business in the 1890s with the main business of pharmaceuticals. It gradually expanded into the vitamin business, contagious medicine and tranquilizers. It entered the gene product industry in the 1980s. Subsequently, the company merged and acquired more than 10 in vitro diagnostic companies. In 1997, The $ 11 billion acquisition of Boehringer Mannhein GmbH's hematology analyzer business and the acquisition of Ventana Medical Systems cancer and infectious disease diagnostics business in 2008 with a $ 3 billion acquisition of various in vitro diagnostic accomplishments.

(2) Siemens: the world's only leading provider of comprehensive therapeutic products and solutions

Founded in 1847, Siemens is one of the world's largest providers of medical equipment with operations in more than 200 countries worldwide. In 2016, Siemens accounted for 10.4% of the global in vitro diagnostic industry.

The rapid development of the company's in vitro diagnostic product line started in 2006 with 1.5 billion euros acquisition of Depp, Imumulite series to absorb immunodiagnosis, followed by the acquisition of Bayer and Dellen, biochemical, immune, molecular and POCT have been formed to become the world's The most complete IVD product line of businesses.

(3) Danaherh: a well-known multinational medical instrument manufacturer, a successful example of global M & A integration

Danaherh is a comprehensive technology company whose products and services span medical, industrial, commercial and other fields and accounted for 10.3% of the global in vitro diagnostic industry in 2016.

The company started a large number of mergers and acquisitions in 1998, followed by continuous horizontal expansion of business to in vitro diagnosis, medicine equipment , Molecular diagnostics In 2016, Danaher fully layout in life sciences and diagnostics, the business accounted for more than 60%.

(4) Abbott: Global, diversified healthcare health care Company, leader in chemiluminescence and blood screening

Abbott is a global, diversified healthcare company with more than 100 years of history and operations in more than 150 countries and territories, accounting for 9.5% of the global in vitro diagnostic industry in 2016.

Abbott Diagnostics focuses on the whole process of early detection, diagnosis and treatment of diseases, and has gradually entered the biochemical, blood glucose, immune, molecular, POCT and development pathways since 1972. Nowadays, blood glucose is the mainstay of the business, and the traditional diagnosis is very mature.

A brief analysis of the domestic IVD industry leader in the development of ways, I hope the future have more excellent enterprise Appeared.The domestic IVD industry is divided into three echelon, the first echelon for foreign giants, the market share of more than 5%; the second echelon for the domestic outstanding enterprises, the market share of 1% -5%; third echelon other domestic Small and medium enterprises, the market share of less than 1%.

We selected four leading representative companies in China: Kehua Biology, Mike Biology, Wanfu Biology and Huada Genes in detail.

Kehua Bio is the first professional manufacturer of diagnostic products listed on the Shenzhen Stock Exchange and currently ranks No.1 in the country for the production of diagnostic reagents. At the beginning of its establishment, it was a biochemical reagent test. After more than 10 years' development, the business expanded to include immunodiagnosis and hematology The company has gradually established a complete industrial chain in the field of medical diagnostics and has a product line of biochemical, immunological, molecular diagnostics and POCT.

The company maintained a steady growth in the past decade, with a CAGR of 15%. In 2016, the biochemical and molecular diagnostics business accounted for 60%.

The early days, the company's main products for the production of reagents, with proxy Sales of Hitachi Biochemical Analyzer, using a combination of self-produced and agency business model. The company focused on independent research and development, 2015 self-produced reagent products 247, including biochemical diagnostic products 141, 86 immune diagnostic products.

At present, the company's biochemical reagents, immunological reagents and instruments to achieve self-production, the first in China to launch chemiluminescence diagnostic products.Company performance steady growth in 2016, the company's total revenue growth rate of 40%, 2011-2016 CAGR of 19% Revenue from self-made reagents remained above 40% of total revenue, with an average annual growth rate of 25%. There is still plenty of room for growth.

Wanfu Bio focuses on the development, production and sales of POCT products in in vitro diagnostics and is the leader in the POCT industry in China.When the company started with pregnancy test products, it gradually developed into drugs, infectious diseases and oncology And many other categories.

The total revenue of Wanfu Biomass has been steadily increasing year by year, with the growth of domestic business reaching over 40%, far exceeding that of foreign countries. Its quantitative testing products (infectious disease testing and chronic disease testing) have become the pillar of performance and the growth rate of chronic disease testing products has reached 40% Performance continued to rise.

(4) Huada gene: China's leading, world-class genetic testing business

Genomics is the world's largest genomics research and development institutions, the company's main business is through genetic testing, for medical institutions, research institutions, enterprises and institutions to provide genomics class diagnostic and research services. Benefit from the second child policy, Gene business structure in the birth health Sequencing services have the strongest growth momentum. In the recent five years, revenue increased from 92 million yuan to 929 million yuan, with a compound annual growth rate of 78.26%. China ranked first in market share.